Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide.
Enfuvirtide is the first of a new class of antiretrovirals know as fusion inhibitors approved for the treatment of HIV infection. It is administered via a subcutaneous injection. The patient is responsible for reconstitution from a powder and self-injection. Nurses caring for patients using enfuvirtide need a solid knowledge base about enfuvirtide administration and side effects in order to effectively educate and manage patients taking enfuvirtide. Enfuvirtide's safety and efficacy reported from phase III trials are summarized. Nursing guidelines were developed by the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide. The guidelines, including suggestions on assessment, education, and management of side effects are reviewed. Teaching tools and resources are offered to assist in patient management. In addition, suggestions for proper syringe disposal and traveling with enfuvirtide are offered.
Foy
Karlissa
K
Community Research Initiative of New England, Boston, MA, USA.
Bradley-Springer
Lucy
L
Kempner
Toni
T
Stevens
Lyn
L
Gahagan
LuAnn
L
D000359:Aftercare / Q000592:standards; D017326:Clinical Trials, Phase III as Topic; D004339:Drug Compounding / Q000592:standards; D016903:Drug Monitoring / Q000451:nursing / Q000592:standards; D004356:Drug Storage / Q000592:standards; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy / Q000451:nursing; D006801:Humans; D020407:Internet; D017744:Medical Waste Disposal / Q000592:standards; D024802:Nurse's Role; D009730:Nursing Assessment / Q000592:standards; D010353:Patient Education as Topic / Q000592:standards; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013664:Teaching Materials; D014195:Travel; D016896:Treatment Outcome
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D017744:Medical Waste Disposal; D010446:Peptide Fragments; D000077560:Enfuvirtide